Grassi Lucia, Maisetta Giuseppantonio, Esin Semih, Batoni Giovanna
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Front Microbiol. 2017 Dec 7;8:2409. doi: 10.3389/fmicb.2017.02409. eCollection 2017.
The great clinical significance of biofilm-associated infections and their inherent recalcitrance to antibiotic treatment urgently demand the development of novel antibiofilm strategies. In this regard, antimicrobial peptides (AMPs) are increasingly recognized as a promising template for the development of antibiofilm drugs. Indeed, owing to their main mechanism of action, which relies on the permeabilization of bacterial membranes, AMPs exhibit a strong antimicrobial activity also against multidrug-resistant bacteria and slow-growing or dormant biofilm-forming cells and are less prone to induce resistance compared to current antibiotics. Furthermore, the antimicrobial potency of AMPs can be highly increased by combining them with conventional (antibiotics) as well as unconventional bioactive molecules. Combination treatments appear particularly attractive in the case of biofilms since the heterogeneous nature of these microbial communities requires to target cells in different metabolic states (e.g., actively growing cells, dormant cells) and environmental conditions (e.g., acidic pH, lack of oxygen or nutrients). Therefore, the combination of different bioactive molecules acting against distinct biofilm components has the potential to facilitate biofilm control and/or eradication. The aim of this review is to highlight the most promising combination strategies developed so far to enhance the therapeutic potential of AMPs against bacterial biofilms. The rationale behind and beneficial outcomes of using AMPs in combination with conventional antibiotics, compounds capable of disaggregating the extracellular matrix, inhibitors of signaling pathways involved in biofilm formation (i.e., quorum sensing), and other peptide-based molecules will be presented and discussed.
生物膜相关感染的重大临床意义及其对抗生素治疗固有的顽固性,迫切需要开发新的抗生物膜策略。在这方面,抗菌肽(AMPs)越来越被认为是开发抗生物膜药物的一个有前景的模板。事实上,由于其主要作用机制依赖于细菌细胞膜的通透化,抗菌肽对多重耐药菌以及生长缓慢或休眠的生物膜形成细胞也表现出强大的抗菌活性,并且与目前的抗生素相比,不太容易诱导耐药性。此外,将抗菌肽与传统(抗生素)以及非传统生物活性分子结合,可以大大提高其抗菌效力。联合治疗在生物膜的情况下显得特别有吸引力,因为这些微生物群落的异质性要求针对处于不同代谢状态(如活跃生长的细胞、休眠细胞)和环境条件(如酸性pH值、缺氧或缺乏营养)的细胞。因此,作用于不同生物膜成分的不同生物活性分子的组合有可能促进生物膜的控制和/或根除。这篇综述的目的是强调迄今为止开发的最有前景的联合策略,以提高抗菌肽对抗细菌生物膜的治疗潜力。将介绍并讨论使用抗菌肽与传统抗生素、能够分解细胞外基质的化合物、参与生物膜形成的信号通路抑制剂(即群体感应)以及其他基于肽的分子联合使用的基本原理和有益结果。